SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    World Medical Association 1997 Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 227:925926.
  • 2
    World Medical Association 2000 Declaration of Helsinki. Ethical principles for medical research involving human subjects. 52nd World Medical Association general assembly. Edinburgh, Scotland, October, 2000.
  • 3
    Ellenberg SS, Temple RT 2000 Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part II: Practical issues and specific cases. Ann Intern Med 133:464470.
  • 4
    Temple R, Ellenberg SS 2000 Placebo controlled trials and active controlled trials in the evaluation of new treatments. Part II: Practical issues and specific cases. Ann Intern Med 133:464470.
  • 5
    World Medical Association 2000 World Medical Association clarification of general assembly text. Available online at http://www.wma.net/e/policy/17-cce.htr. Accessed September 2002.
  • 6
    Committee for Proprietary Medical Product (CPMP) 2001 Note for guidance on post menopausal osteoporosis in women. Available online at http://www.emea.eu.int/pdfs/human/ewp/055295en.pdf. Accessed September 2002.
  • 7
    Anonymous Consensus Development Conference 1994 Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646650.
  • 8
    Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A 2001 The burden of osteoporotic fractures: A method for setting intervention thresholds. Osteoporos Int 12:417427.
  • 9
    Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, Berger M 2001 Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. JBMR 15:721727.
  • 10
    Johnell O, Oden A, Caulin F, Kanis JA 2001 Acute and long-term increase in fracture risk after hospitalisation for vertebral fracture. Osteoporos Int 12:207214.
  • 11
    World Health Organisation 1994 Assessment of osteoporotic fracture risk and its role for screening for postmenopausal osteoporosis. WHO Technical Report Series 843. Geneva, Switzerland.
  • 12
    Kanis JA, Melton LJ, Christiansen C, Johnston C, Khaltaev N 1994 The diagnosis of osteoporosis. J Bone Miner Res 9:11371141.
  • 13
    Kanis JA, Johnell O, Oden A, de Laet C, Mellstrom D 2001 Diagnosis of osteoporosis and fracture threshold in men. Calcif Tissue Int 69:218221.
  • 14
    Kanis JA, Gluer C-C for the Committee of Scientific Advisors, International Osteoporosis Foundation 2000 An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 11:192202.
  • 15
    National Osteoporosis Foundation 1998 Osteoporosis: Review of the evidence for prevention, diagnosis and treatment, and cost-effectiveness analysis. Status Report. Osteoporos Int 8(Suppl 4):188.
  • 16
    European Commission 1998 Report on osteoporosis in the European Community. Action for Prevention. Directorate General for Employment, Industrial Relations and Social Affairs. Directorate V/F. 2. Office for Official Publications of the European Communities, Luxemborg.
  • 17
    Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D on behalf of the EFFO 1997 Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 7:390406.
  • 18
    Royal College of Physicians 1999 Guidelines for the Prevention and Treatment of Osteoporosis. London, UK, RCP.
  • 19
    Food and Drug Administration 1994 Guidelines for Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis. Division of Metabolism and Endocrine Drug Products, FDA, Bethesda, MD, USA.
  • 20
    Cummings SR, Black DM, Thompson DE et al. 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results From the Fracture Intervention Trial. JAMA 280:20772082.
  • 21
    Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portalis J, Downs RW, Dequeker J, Favas M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB for the Alendronate Phase III Treatment Study Group 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:14371443.
  • 22
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FC, Eckert S, Ensrud KF, Avioli LV, Lips P, Cummings SR for the Multiple Outcomes of Raloxifene Evaluation (MORE) investigators 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results From a 3-year randomised clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637645.
  • 23
    Chesnut H, Silvermann S, Andriano K, Genant HK, Gimona A, Harris S, Keil D, LeBoff M, Maricec M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D for the PROOF study group 2000 A randomised trial of nasal spray Salmon Calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. Am J Med 10:267276.
  • 24
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thomspon DE, Nevitt C, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE for the Fracture Intervention Trial Research Group 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:15351541.
  • 25
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyeri MS, Axelrod DW, Miffer PD for the Vertebral Efficacy with risedronate therapy (VERT) Study Group 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:13441352.
  • 26
    Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group 2000 Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 11:8391.
  • 27
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Estell R, Meunier PJ, Reginster J-Y, for the Hip Intervention Program Study Group 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333340.
  • 28
    Kanis JA, Brazier J, Calvert N, Lloyd-Jones M, Stevenson M 2002 Treatment of established osteoporosis. A systematic review and cost-utility analysis. A report for the National Co-ordinating Centre for Health Technology Assessment. Health Technology Assessment (in press)
  • 29
    Chapuy MC, Arlot ME, Delmas PD, Meunier PJ 1994 Effect of calcium and cholecalciferol treatment of three years on hip fracture in elderly women. BMJ 308:10811082.
  • 30
    Kanis JA, Oden A, Johnell O, Caulin F, Bone H, Alexandre J-M, Abadie E, Lekkerkerker F 2002 Uncertain future of trials in osteoporosis. Osteoporos Int 13:443449.
  • 31
    Rawles J 1998 Understanding clinical trials: The number of patients required in a clinical trial. Br J Cardiol 5:170171.
  • 32
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceutical for Human Use 1999 ICH tripartite guidelines statistical principle for clinical trials (ICHE9). Available online at http://www.ifpma.org/pdifpma/e9.pdf. Accessed September 2002.
  • 33
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceutical for human Use 1999 ICH tripartite guidelines choice of the control group and related issues in clinical trials (ICHE10). Available online at http://www.ifpma.org/pdifpma/e10.step4.pdf. Accessed September 2002.
  • 34
    Temple R, Ellenberg SS 2000 Placebo controlled trials and active controlled trials in the evaluation of new treatments. Part I: Ethical and scientific issues. Ann Intern Med 133:455463.
  • 35
    Temple R 1983 Difficulties in evaluating positive control trials. Proc Am Stat Assoc 4:17.
  • 36
    Jones B, Jarvis P, Lewis JA, Ebbutt AF 1996 Trials to assess equivalence: The importance of rigorous methods. BMJ 313:3639.
  • 37
    World Health Organization 1998 Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis. World Health Organization, Geneva, Switzerland.
  • 38
    Wasnich GR 2001 Variation in biochemical markers of bone turnover sources, quantification, minimisation. In: EastellR, et al (eds.) Bone Markers Biochemical and Clinical Perspective. Martin Dunitz, London, UK, pp. 131139.
  • 39
    Kanis JA, Oden A, Johnell O 2001 Acute and long-term increase in fracture risk after hospitalisation for stroke. Stroke 32:702706.